Analysts Offer Insights on Healthcare Companies: Idexx Laboratories (IDXX) and Alcon (ALC)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Idexx Laboratories (IDXX) and Alcon (ALC).
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Idexx Laboratories (IDXX)
Stifel Nicolaus analyst Jonathan Block maintained a Buy rating on Idexx Laboratories today and set a price target of $675.00. The company’s shares closed last Wednesday at $573.61.
According to TipRanks.com, Block is a 4-star analyst with an average return of
Currently, the analyst consensus on Idexx Laboratories is a Moderate Buy with an average price target of $701.29, implying a 24.8% upside from current levels. In a report released yesterday, TipRanks – OpenAI also upgraded the stock to Buy with a $625.00 price target.
See the top stocks recommended by analysts >>
Alcon (ALC)
William Blair analyst Steven Lichtman maintained a Hold rating on Alcon today. The company’s shares closed last Wednesday at $66.25.
According to TipRanks.com, Lichtman is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Alcon with a $96.73 average price target, implying a 46.4% upside from current levels. In a report issued on April 24, TipRanks – Anthropic also reiterated a Hold rating on the stock with a CHF65.00 price target.
Read More on IDXX:
Disclaimer & DisclosureReport an Issue
- Erin Wright Reiterates Buy on Idexx After Earnings Beat, Raised 2026 Outlook, and Lifts Price Target to $805
- IDEXX Laboratories Lifts Guidance on Robust Q1
- Idexx Laboratories price target lowered to $660 from $790 at BofA
- Idexx Laboratories reports Q1 EPS $3.47, consensus $3.41
- Idexx Laboratories raises FY26 EPS view to $14.45-$14.90 from $14.29-$14.80
